| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|---|---|---|---|---|---|---|
CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||
Net loss | |||||||
-13,294 | -13,900 | -16,235 | -21,436 | -20,027 | -15,788 | -12,088 | -9,675 |
Adjustments to reconcile net loss to net cash flows from operating activities: | |||||||
Payment of preferred stock dividends | |||||||
394 | 0 | - | - | - | - | - | - |
Depreciation and amortization | |||||||
- | - | 1 | 7 | 7 | 10 | 12 | 9 |
Stock-based compensation expense | |||||||
1,683 | 4,445 | 1,101 | 2,479 | 3,400 | 4,070 | 3,789 | 2,792 |
Amortization of right to use lease asset | |||||||
35 | - | - | - | - | - | - | - |
Issuance of common stock for services | |||||||
- | 12 | 33 | - | - | - | - | - |
Loss from equity method investment in Galectin Sciences LLC | |||||||
- | - | - | - | - | -400 | - | - |
Non-cash interest expense | |||||||
87 | 336 | 12 | - | - | - | - | - |
Changes in operating assets and liabilities: | |||||||
Prepaid expenses and other assets | |||||||
356 | -19 | -8 | -122 | 21 | 335 | 39 | 55 |
Accounts payable and accrued expenses | |||||||
997 | -1,091 | -812 | 2,419 | -342 | -783 | 848 | -577 |
Other long-term liabilities | |||||||
- | - | - | - | - | - | -6 | 6 |
Net cash used in operating activities | |||||||
- | - | - | -16,409 | -16,983 | -12,426 | -7,484 | -7,500 |
Equity method investment in Galectin Sciences LLC | |||||||
- | - | - | - | - | 400 | - | - |
Net cash from operating activities | |||||||
-10,848 | -10,179 | -15,892 | - | - | - | - | - |
CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||
Purchases of property and equipment | |||||||
- | - | - | - | - | 0 | 0 | 5 |
Change in restricted cash and security deposit | |||||||
- | - | - | - | - | 0 | 0 | -69 |
Net cash from investing activities | |||||||
- | - | - | 0 | 0 | -400 | - | 64 |
Net cash from investing activities | |||||||
- | - | 0 | - | - | - | - | - |
CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||
Net proceeds from issuance of common stock and warrants | |||||||
50,469 | 15,379 | 3,583 | 5,925 | 13,701 | 29,337 | 3,833 | 10,403 |
Net proceeds from exercise of common stock warrants and options | |||||||
- | - | - | - | - | 2,128 | 4,776 | - |
Net cash provided by financing activities | |||||||
- | - | - | 5,925 | 13,701 | 31,465 | 8,609 | 10,403 |
Net cash from financing activities | |||||||
50,075 | 15,379 | 3,583 | - | - | - | - | - |
NET DECREASE IN CASH AND CASH EQUIVALENTS | |||||||
39,227 | 5,200 | - | - | - | - | - | - |
NET INCREASE IN CASH AND CASH EQUIVALENTS | |||||||
- | - | -12,309 | -10,484 | -3,282 | 18,639 | 1,125 | 2,967 |
NONCASH FINANCING ACTIVITIES: | |||||||
Payment of preferred stock dividends in common stock | |||||||
102 | 915 | 1,232 | 742 | 868 | 943 | 867 | 976 |
Common stock purchase warrants issued in connection with line of credit | |||||||
- | - | 696 | - | - | - | - | - |